OBJECTIVES: To study the incidence and prevalence of primary systemic vasculitides (PSV) in the Costa del Sol region (southern Spain) and to compare the major epidemiological studies in PSV with the results obtained in our area. METHODS: Retrospective study including permanent residents ≥14 years (or older) diagnosed with PSV at the Hospital Costa del Sol (Marbella, Spain) between 1994 and 2010. Epidemiological data were collected and the annual incidence rate during the study period and the prevalence in 2010 were calculated per million population, except for GCA, which was estimated per 100,000 population >50 years. RESULTS: Seventy-four adult patients were diagnosed with PSV, representing an annual incidence of 15.8 (95%CI 12.2-19.4) patients/million population. These diagnoses included 29 (39.1%) giant cell arteritis (GCA), 5 (6.7%) Takayasu's arteritis (TKA), 3 (4%) poly-arteritis nodosa (PAN), 29 (39.1%) antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) [10 (13.5%) granulomatosis with polyangiitis (GPA) (Wegener), 16 (21.6%) microscopic polyangiitis (MPA) and 3 (4%) eosinophilic granulomatosis with polyangiitis (EGPA) (Churg-Strauss)], 7 (9.4%) IgA vasculitis (Henoch-Schönlein) (IgAV) and one (1.3%) cryobulinaemic vasculitis (CV). The annual incidence and 2010 prevalence for each of the PSV, respectively, were: GCA: 2.2/12.2; TKA: 1.1/10.5; PAN: 0.6/2.6; AAV: 6.2/44.8 (GPA: 2.1/15.8; MPA: 3.4/23.8; EGPA: 0.6/5.3); IgAV: 1.5/7.9; and CV: 0.2/0. CONCLUSIONS: The first epidemiological study of PSV in southern Spain corroborates their infrequency, with GCA and AAV as the PSV most often diagnosed. In southern Spain, the incidence and prevalence of PSV are lower than in northern Spain and in countries in the Northern Hemisphere.
OBJECTIVES: To study the incidence and prevalence of primary systemic vasculitides (PSV) in the Costa del Sol region (southern Spain) and to compare the major epidemiological studies in PSV with the results obtained in our area. METHODS: Retrospective study including permanent residents ≥14 years (or older) diagnosed with PSV at the Hospital Costa del Sol (Marbella, Spain) between 1994 and 2010. Epidemiological data were collected and the annual incidence rate during the study period and the prevalence in 2010 were calculated per million population, except for GCA, which was estimated per 100,000 population >50 years. RESULTS: Seventy-four adult patients were diagnosed with PSV, representing an annual incidence of 15.8 (95%CI 12.2-19.4) patients/million population. These diagnoses included 29 (39.1%) giant cell arteritis (GCA), 5 (6.7%) Takayasu's arteritis (TKA), 3 (4%) poly-arteritis nodosa (PAN), 29 (39.1%) antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) [10 (13.5%) granulomatosis with polyangiitis (GPA) (Wegener), 16 (21.6%) microscopic polyangiitis (MPA) and 3 (4%) eosinophilic granulomatosis with polyangiitis (EGPA) (Churg-Strauss)], 7 (9.4%) IgA vasculitis (Henoch-Schönlein) (IgAV) and one (1.3%) cryobulinaemic vasculitis (CV). The annual incidence and 2010 prevalence for each of the PSV, respectively, were: GCA: 2.2/12.2; TKA: 1.1/10.5; PAN: 0.6/2.6; AAV: 6.2/44.8 (GPA: 2.1/15.8; MPA: 3.4/23.8; EGPA: 0.6/5.3); IgAV: 1.5/7.9; and CV: 0.2/0. CONCLUSIONS: The first epidemiological study of PSV in southern Spain corroborates their infrequency, with GCA and AAV as the PSV most often diagnosed. In southern Spain, the incidence and prevalence of PSV are lower than in northern Spain and in countries in the Northern Hemisphere.
Authors: P Elfving; O Marjoniemi; H Niinisalo; A Kononoff; L Arstila; E Savolainen; J Rutanen; O Kaipiainen-Seppänen Journal: Rheumatol Int Date: 2016-04-06 Impact factor: 2.631
Authors: Dan Pugh; Maira Karabayas; Neil Basu; Maria C Cid; Ruchika Goel; Carl S Goodyear; Peter C Grayson; Stephen P McAdoo; Justin C Mason; Catherine Owen; Cornelia M Weyand; Taryn Youngstein; Neeraj Dhaun Journal: Nat Rev Dis Primers Date: 2022-01-06 Impact factor: 65.038
Authors: Irena Doubelt; David Cuthbertson; Simon Carette; Sharon A Chung; Lindsy J Forbess; Nader A Khalidi; Curry L Koening; Carol Langford; Carol A McAlear; Larry W Moreland; Paul A Monach; Philip Seo; Ulrich Specks; Robert F Spiera; Jason M Springer; Antoine G Sreih; Kenneth J Warrington; Peter A Merkel; Christian Pagnoux Journal: ACR Open Rheumatol Date: 2021-05-25
Authors: F David Carmona; Patrick Coit; Güher Saruhan-Direskeneli; José Hernández-Rodríguez; María C Cid; Roser Solans; Santos Castañeda; Augusto Vaglio; Haner Direskeneli; Peter A Merkel; Luigi Boiardi; Carlo Salvarani; Miguel A González-Gay; Javier Martín; Amr H Sawalha Journal: Sci Rep Date: 2017-03-09 Impact factor: 4.379
Authors: Germán Sánchez-Díaz; Francisco Escobar; Ana Villaverde-Hueso; Manuel Posada de la Paz; Verónica Alonso-Ferreira Journal: Int J Environ Res Public Health Date: 2019-04-17 Impact factor: 3.390
Authors: Vibeke Strand; Sophie Dimonaco; Katie Tuckwell; Micki Klearman; Neil Collinson; John H Stone Journal: Arthritis Res Ther Date: 2019-02-20 Impact factor: 5.156
Authors: Mugdha Gokhale; Christopher F Bell; Scott Doyle; Jolyon Fairburn-Beech; Jonathan Steinfeld; Melissa K Van Dyke Journal: J Clin Rheumatol Date: 2021-04-01 Impact factor: 3.902
Authors: Megan Rutter; Jonathan Bowley; Peter C Lanyon; Matthew J Grainge; Fiona A Pearce Journal: Rheumatology (Oxford) Date: 2021-11-03 Impact factor: 7.580